全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Marc Espié , Patricia de Cremoux ...
来源:[J].Breast Cancer Research(IF 5.872), 2017, Vol.19 (1)Springer
摘要:This study investigated the value of some clinicopathological parameters and 18 F-fluorodeoxyglucose-positron emission tomography/computed tomography (18FDG-PET/CT) indices, including textural features, to predict event-free survival (EFS) in estrogen receptor-positive...
作者:Marc Espié , Pascal Merlet
来源:[J].European Journal of Nuclear Medicine and Molecular Imaging(IF 5.114), 2017, Vol.44 (7), pp.1145-1154Springer
摘要:The study was designed to evaluate 1) the relationship between PET image textural features (TFs) and SUVs, metabolic tumour volume (MTV), total lesion glycolysis (TLG) and tumour characteristics in a large prospective and homogenous cohort of oestrogen receptor-positive (ER+) bre...
作者:Marc Espié , Nathalie Siauve ...
来源:[J].BMC Cancer(IF 3.333), 2011, Vol.11 (1)Springer
摘要:Abstract(#br) Background(#br)To illustrate that Breast-MRI performed in high spatial resolution and low temporal resolution (1 minute) allows the measurement of kinetic parameters that can assess the final pathologic response to neoadjuvant chemotherapy in breast cancer.(#br) Met...
作者:Marc Espié , Alain Lortholary ...
来源:[J].The Breast(IF 2.491), 2018, Vol.41, pp.1-7Elsevier
摘要:Abstract(#br)Background(#br)Cardiac toxicity with a decrease of the left ventricular ejection fraction (LVEF) is the main side effect induced by trastuzumab. This study reports the fluctuation of LVEF over the 12 months of adjuvant trastuzumab in PHARE trial (NCT00381901).(#br)Me...
作者:Marc Espié , Pierre Fumoleau ...
来源:[J].The Lancet(IF 39.06), 2019, Vol.393 (10191), pp.2591-2598Elsevier
摘要:Summary(#br)Background(#br)In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced Exposure (PHARE) trial could not show that 6 months of adjuvant trastuzumab was non-inferior to 12 months. Here, we report the planned final analysis based...
作者:Marc Espié , Stéphanie Perot ...
来源:[J].Supportive Care in Cancer(IF 2.649), 2017, Vol.25 (3), pp.973-982Springer
摘要:Abstract(#br) Purpose(#br)This report describes the results of an observational, retrospective cohort study, evaluating the use of iron sucrose (IS) and red blood cell (RBC) transfusions in patients with cancer in routine clinical practice in France. A parallel investigated ...
作者:... Edwige Bourstyn , Marc Espié , Christophe Hennequin
来源:[J].Radiotherapy and Oncology(IF 4.52), 2016Elsevier
摘要:Abstract(#br)Purpose(#br)Breast conserving treatment, consisting of lumpectomy followed by whole-breast irradiation, is considered the standard of care in early-stage breast cancer. Randomized studies have reported that delivering boost doses to tumor bed improves local cont...
作者:... Catherine Poirot , Mohamed Habdous , Marc Espié
来源:[J].Reproductive BioMedicine Online(IF 2.675), 2014, Vol.29 (5), pp.573-580Elsevier
摘要:Abstract(#br)Anti-Müllerian hormone (AMH) levels fall during chemotherapy. Treatment-induced amenorrhoea is a reversible phenomenon, but few data are available on long-term AMH changes in breast cancer. The aim of the study was to describe serum AMH levels before, during and...
作者:Marc Espié , Florence Dalenc ...
来源:[J].Bulletin du Cancer(IF 0.605), 2014, Vol.101 (9), pp.780-788Elsevier
摘要:Abstract(#br)The international phase IIIb study, ATHENA assessed the combination of bevacizumab/taxane-based chemotherapy in the first-line treatment of HER2negative metastatic breast cancer (mBC) in real-life setting. Among the 365patients included in France, median overall surv...
作者:Marc Espié , Bernard Asselain ...
来源:[J].Thérapie(IF 0.374), 2015, Vol.70 (5), pp.433-441Elsevier
摘要:Abstract(#br)Objective(#br)To evaluate the overall cancer risk, primarily breast cancer, for women exposed to diethylstilbestrol (DES) in utero in France.(#br)Methods(#br)A cohort of 3 436 prenatally DES exposed women and a comparable cohort of 3 256 unexposed women were recruite...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×